Berta G. Arbol

Berta G. Arbol

Auto-generated profile, based on publicly available information

Berta G. Arbol

Ajmera Transplant Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
Javier Tomas Solera RalloJavier Tomas Solera Rallo
Javier Tomas Solera Rallo
BÁBerta G. Árbol
Berta G. Árbol
IBIlona Bahinskaya
Ilona Bahinskaya
NMNikki Marks
Nikki Marks
AHAtul Humar
Atul Humar
DKDeepali Kumar
Deepali Kumar
Solid organ transplant recipients (SOTr) remain at risk of severe COVID-19. Several previous early therapies are no longer effective against new circulating variants. We performed a prospective cohort study in outpatient adult SOTr during the omicron BA.2 wave (April–May 2022), to determine the effectiveness of 3 doses of remdesivir given within 7 days of symptoms onset. Patients were followed for at least 30 days. The primary outcome was hospitalization. Of 210 SOTr that had COVID-19, we included 192. The median age was 54.5 years and 61.5% were men. The most common transplants were kidney (41.7%), lung (19.3%), liver (18.8%), and heart (6.3%). Most patients (90.1%) had previously received ≥3 COVID-19 vaccine doses. Fifteen (7.8%) were hospitalized, 5(2.6%) required supplemental oxygen, 3(1.6%) ICU admission, and 2(1%) mechanical ventilation with 2(1%) deaths. Age, the number of comorbidities, prednisone chronic treatment, and lung transplant were risk factors for hospitalization. Early remdesivir significantly decreased the hospitalization rate: adjusted hazard ratio 0.12 (95% CI: 0.03–0.57). The adjusted number needed to treat to prevent one hospitalization was 15.2 (95% CI: 13.6–31.4). No patient that received early remdesivir needed ICU admission or died. In a cohort of SOTr with COVID-19 infection, administration of 3-dose early remdesivir independently reduced the disease severity.

17 March 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
Javier Tomas Solera RalloJavier Tomas Solera Rallo
Javier Tomas Solera Rallo
BÁBerta G. Árbol
Berta G. Árbol
AMAnkit Mittal
Ankit Mittal
VHVictoria Hall
Victoria Hall
TMTina Marinelli
Tina Marinelli
DKDeepali Kumar
Deepali Kumar
Data regarding COVID-19 outcomes in solid organ transplant recipients(SOTr) across SARS-CoV-2 waves, including the impact of different measures, is lacking. This cohort study, conducted from March 2020-May 2023 in Toronto, Canada, aimed to analyze COVID-19 outcomes in 1,975 SOTr across various SARS-CoV-2 waves and assess the impact of preventive and treatment measures. The primary outcome was severe COVID-19, defined as requiring supplemental oxygen, with secondary outcomes including hospitalization, length of stay, ICU admission, and 30-day and 1-year all-cause mortality. SARS-CoV-2 waves were categorized as Wildtype/Alpha/Delta(318 cases, 16.1%), Omicron-BA.1(268, 26.2%), Omicron-BA.2(268, 13.6%), Omicron-BA.5(561, 28.4%), Omicron-BQ.1.1(188, 9.5%), and Omicron-XBB.1.5(123, 6.2%). Severe COVID-19 rate was highest during the Wildtype/Alpha/Delta wave(44.6%), and lower in Omicron waves(5.7-16.1%). Lung transplantation was associated with severe COVID-19(OR:4.62, 95%CI:2.71-7.89), along with rituximab treatment(OR:4.24, 95%CI:1.04-17.3), long-term corticosteroid use(OR:3.11, 95%CI:1.46-6.62), older age(OR: 1.51, 95%CI:1.30-1.76), chronic lung disease(OR:2.11, 95%CI:1.36-3.30), chronic kidney disease(OR:2.18, 95%CI:1.17-4.07), and diabetes(OR:1.97, 95%CI:1.37-2.83). Early treatment and ≥3 vaccine doses were associated with reduced severity(OR: 0.29, 95%CI:0.19-0.46, and 0.35, 95%CI:0.21-0.60, respectively). Tixagevimab/cilgavimab and bivalent boosters did not show a significant impact. The study concludes that COVID-19 severity decreased across different variants in SOTr. Lung transplantation was associated with worse outcomes and may benefit more from preventive and early therapeutic interventions.

4 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
VFVictor H. Ferreira
Victor H. Ferreira
Javier Tomas Solera RalloJavier Tomas Solera Rallo
Javier Tomas Solera Rallo
QHQueenie Hu
Queenie Hu
VHVictoria G. Hall
Victoria G. Hall
BABerta G. Arbol
Berta G. Arbol
AHAtul Humar
Atul Humar
Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools. We identify that partially or fully-vaccinated transplant recipients after infection with Omicron BA.1 have the greatest BA.1 neutralizing antibody and BA.1-specific polyfunctional CD4+and CD8+T-cell responses, with potent cross-neutralization against BA.2. In these patients, the magnitude of the BA.1-directed response is comparable to immunocompetent triple-vaccinated controls. A subset of patients with pre-Omicron infection have heterotypic responses to BA.1 and BA.2, whereas uninfected transplant patients with three doses of vaccine demonstrate the weakest comparative responses. These results have implications for risk of infection, re-infection, and disease severity among immune compromised hosts with Omicron infection.